parpi Search Results


93
TargetMol cancer cells
Cancer Cells, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/Parpi/10__3390_slash_biomedicines13040958-83-11-35
Average 93 stars, based on 1 article reviews
cancer cells - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Tocris parp 1 2 inhibitor
Parp 1 2 Inhibitor, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/PARPi-FL/us12421241-1196-17-21
Average 93 stars, based on 1 article reviews
parp 1 2 inhibitor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Tocris parpi fl
Parpi Fl, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/PARPi-FL/pmc08249464-271-8-9
Average 93 stars, based on 1 article reviews
parpi fl - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Jannetti Publications radioiodinated parpi
Radioiodinated Parpi, supplied by Jannetti Publications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/radioiodinated+parpi/pmc06723032-271-13-8
Average 90 stars, based on 1 article reviews
radioiodinated parpi - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck KGaA parpi (niraparib)
A LUAD cell lines harboring deficiency of SMARCA4 (A549 and H1299), ARID1A (H2172 and SK-LU-1), and PBRM1 (ABC1 and H226) were constitutively expressed the corresponding wild-type proteins via lentiviral cDNA expression system. Expression of SMARCA4, ARID1A, and PBRM1 proteins was analyzed by western blotting. β-Actin was detected as loading control. B Cell viability screening for tuvusertib (0, 3.9–1000 nM) in combination with lartesertib (0, 39.1–10000 nM), peposertib (0, 39.1–10000 nM), or <t>niraparib</t> (0, 39.1-10000 nM). Cells were treated with these combinations for 4 days, then a cell viability assay was performed. Using SynergyFinder plus, dose response and Bliss synergy maps in A549 cells are shown in Fig. 1B, and other cells are shown in Fig. . These maps indicate the mean of three independent experiments. C Combination sensitivity score-Bliss synergy score plots of tuvusertib in combination with lartesertib, peposertib, or niraparib in the cell viability screening shown in Fig. 1B.
Parpi (Niraparib), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/parpi++niraparib+/pmc11775187-303-7-16
Average 90 stars, based on 1 article reviews
parpi (niraparib) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd olaparib parpi
(A) Proliferation of Pmel-1 CD8 + T cells activated with gp100 ex vivo. CTV histograms of live, CD44 hi CD8 + T cells at indicated times post-activation are shown. Red histograms are un-activated CD8 + T cells that have largely died. The number of divisions is shown. (B) Immunoblots of CD8 + T whole-cell extracts prepared the same number of cells at 0 and 30 h post-activation. (C) CD8 + T cells were activated and treated with 5 μM AZD6738 (ATRi) from 0 to 24 h (blue) or 24 to 48 h (red). At 48 h, live CD8 + T cells (eFluor 780 − CD8 + TCRβ + ) were quantitated. (D) Unactivated CD8 + T cells were maintained in IL-7 and treated with ATRi from 0 to 24 or 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (E) CD8 + T cells were activated and treated with ATRi, 500 nM AZD0156 (ATMi), 5 μM <t>olaparib</t> <t>(PARPi),</t> or 500 nM AZD1775 (WEE1i) from 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (A and B) Two biological replicates. (C and D) Three biological replicates. (E) Two biological replicates; three technical replicates. (C–E) Mean and SD bars are shown. *p < 0.05, **p < 0.01, ****p < 0.0001, by ANOVA with Tukey’s multiple comparisons.
Olaparib Parpi, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/parpi+olaparib/pmc09646445-45-0-3
Average 90 stars, based on 1 article reviews
olaparib parpi - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Firstline Biopharmaceuticals Corporation single-agent parpi rucaparib
(A) Proliferation of Pmel-1 CD8 + T cells activated with gp100 ex vivo. CTV histograms of live, CD44 hi CD8 + T cells at indicated times post-activation are shown. Red histograms are un-activated CD8 + T cells that have largely died. The number of divisions is shown. (B) Immunoblots of CD8 + T whole-cell extracts prepared the same number of cells at 0 and 30 h post-activation. (C) CD8 + T cells were activated and treated with 5 μM AZD6738 (ATRi) from 0 to 24 h (blue) or 24 to 48 h (red). At 48 h, live CD8 + T cells (eFluor 780 − CD8 + TCRβ + ) were quantitated. (D) Unactivated CD8 + T cells were maintained in IL-7 and treated with ATRi from 0 to 24 or 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (E) CD8 + T cells were activated and treated with ATRi, 500 nM AZD0156 (ATMi), 5 μM <t>olaparib</t> <t>(PARPi),</t> or 500 nM AZD1775 (WEE1i) from 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (A and B) Two biological replicates. (C and D) Three biological replicates. (E) Two biological replicates; three technical replicates. (C–E) Mean and SD bars are shown. *p < 0.05, **p < 0.01, ****p < 0.0001, by ANOVA with Tukey’s multiple comparisons.
Single Agent Parpi Rucaparib, supplied by Firstline Biopharmaceuticals Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/single+agent+parpi+rucaparib/pm39255537-154-26-26
Average 90 stars, based on 1 article reviews
single-agent parpi rucaparib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Clovis Oncology parpi rucaparib
(A) mCRPC patients were enrolled in a Phase Ib <t>rucaparib/nivolumab</t> co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.
Parpi Rucaparib, supplied by Clovis Oncology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/parpi+rucaparib/bio_rxiv__2020__07__17__198598-49-23-25
Average 90 stars, based on 1 article reviews
parpi rucaparib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Neuroscience Information Framework parpi nif
(A) mCRPC patients were enrolled in a Phase Ib <t>rucaparib/nivolumab</t> co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.
Parpi Nif, supplied by Neuroscience Information Framework, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/parpi+nif/pm40038300-322-277-160
Average 90 stars, based on 1 article reviews
parpi nif - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd quinazolinone- and phthalazinone-based parpi collection
(A) mCRPC patients were enrolled in a Phase Ib <t>rucaparib/nivolumab</t> co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.
Quinazolinone And Phthalazinone Based Parpi Collection, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/quinazolinone++and+phthalazinone+based+parpi+collection/pm37570820-150-15-7
Average 90 stars, based on 1 article reviews
quinazolinone- and phthalazinone-based parpi collection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Neuroscience Information Framework residual cells isolated from parpi-treated tumors
(A) mCRPC patients were enrolled in a Phase Ib <t>rucaparib/nivolumab</t> co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.
Residual Cells Isolated From Parpi Treated Tumors, supplied by Neuroscience Information Framework, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/residual+cells+isolated+from+parpi+treated+tumors/pm40038300-246-1-14
Average 90 stars, based on 1 article reviews
residual cells isolated from parpi-treated tumors - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Jiangsu Hengrui Medicine parpi fluzoparib
(A) mCRPC patients were enrolled in a Phase Ib <t>rucaparib/nivolumab</t> co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.
Parpi Fluzoparib, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/parpi/parpi+fluzoparib/10__2147_slash_cmar__s265327-38-1-8
Average 90 stars, based on 1 article reviews
parpi fluzoparib - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A LUAD cell lines harboring deficiency of SMARCA4 (A549 and H1299), ARID1A (H2172 and SK-LU-1), and PBRM1 (ABC1 and H226) were constitutively expressed the corresponding wild-type proteins via lentiviral cDNA expression system. Expression of SMARCA4, ARID1A, and PBRM1 proteins was analyzed by western blotting. β-Actin was detected as loading control. B Cell viability screening for tuvusertib (0, 3.9–1000 nM) in combination with lartesertib (0, 39.1–10000 nM), peposertib (0, 39.1–10000 nM), or niraparib (0, 39.1-10000 nM). Cells were treated with these combinations for 4 days, then a cell viability assay was performed. Using SynergyFinder plus, dose response and Bliss synergy maps in A549 cells are shown in Fig. 1B, and other cells are shown in Fig. . These maps indicate the mean of three independent experiments. C Combination sensitivity score-Bliss synergy score plots of tuvusertib in combination with lartesertib, peposertib, or niraparib in the cell viability screening shown in Fig. 1B.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: A LUAD cell lines harboring deficiency of SMARCA4 (A549 and H1299), ARID1A (H2172 and SK-LU-1), and PBRM1 (ABC1 and H226) were constitutively expressed the corresponding wild-type proteins via lentiviral cDNA expression system. Expression of SMARCA4, ARID1A, and PBRM1 proteins was analyzed by western blotting. β-Actin was detected as loading control. B Cell viability screening for tuvusertib (0, 3.9–1000 nM) in combination with lartesertib (0, 39.1–10000 nM), peposertib (0, 39.1–10000 nM), or niraparib (0, 39.1-10000 nM). Cells were treated with these combinations for 4 days, then a cell viability assay was performed. Using SynergyFinder plus, dose response and Bliss synergy maps in A549 cells are shown in Fig. 1B, and other cells are shown in Fig. . These maps indicate the mean of three independent experiments. C Combination sensitivity score-Bliss synergy score plots of tuvusertib in combination with lartesertib, peposertib, or niraparib in the cell viability screening shown in Fig. 1B.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques: Expressing, Western Blot, Control, Viability Assay

A Western blot analysis of SMARCA4 wild-type (WT) and knockout (KO) H1975 cells. α-Tubulin was detected as loading control. B Cell viability for tuvusertib or niraparib alone. Cells were treated with tuvusertib (0, 3.9–1000 nM) and niraparib (0, 39–10000 nM) combination for 6 days, then a cell viability assay was performed. These graphs indicate the mean ± SD of four independent experiments. C Cell viability at 62.5 nM tuvusertib and 625 nM niraparib in the experiment shown in Fig. 2B. The graph indicates the mean ± SD of four independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001. D Representative images of each samples show each and merged images of DAPI (blue), PCNA (green), and γH2A.X (red). Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib each alone and combination for 48 h, then carried on immunofluorescence analysis. Scale bars indicate 50 µm. E QIBC plots of DAPI sum intensity versus PCNA mean intensity, with γH2A.X mean intensity (color scale) per nuclei in the experiment shown in Fig. 2D. These plots indicate 2000 cells. F Dot plot of γH2A.X mean intensity per nuclei in S phase cells in the experiment shown in Fig. 2D. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001. G Representative images of each samples show merged images of DAPI (blue) and PLA foci of EdU and γH2A.X (red). Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib each alone and combination for 48 h, then carried on PLA analysis. Scale bars indicate 10 µm. H Quantification of the average number of PLA foci per positive nuclei (foci ≥ 1) in S phase cells. The graph indicates the mean ± SD of four independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: not significant (ns) > 0.05 and * ≤ 0.05.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: A Western blot analysis of SMARCA4 wild-type (WT) and knockout (KO) H1975 cells. α-Tubulin was detected as loading control. B Cell viability for tuvusertib or niraparib alone. Cells were treated with tuvusertib (0, 3.9–1000 nM) and niraparib (0, 39–10000 nM) combination for 6 days, then a cell viability assay was performed. These graphs indicate the mean ± SD of four independent experiments. C Cell viability at 62.5 nM tuvusertib and 625 nM niraparib in the experiment shown in Fig. 2B. The graph indicates the mean ± SD of four independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001. D Representative images of each samples show each and merged images of DAPI (blue), PCNA (green), and γH2A.X (red). Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib each alone and combination for 48 h, then carried on immunofluorescence analysis. Scale bars indicate 50 µm. E QIBC plots of DAPI sum intensity versus PCNA mean intensity, with γH2A.X mean intensity (color scale) per nuclei in the experiment shown in Fig. 2D. These plots indicate 2000 cells. F Dot plot of γH2A.X mean intensity per nuclei in S phase cells in the experiment shown in Fig. 2D. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: ** ≤ 0.01, *** ≤ 0.001, and **** ≤ 0.0001. G Representative images of each samples show merged images of DAPI (blue) and PLA foci of EdU and γH2A.X (red). Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib each alone and combination for 48 h, then carried on PLA analysis. Scale bars indicate 10 µm. H Quantification of the average number of PLA foci per positive nuclei (foci ≥ 1) in S phase cells. The graph indicates the mean ± SD of four independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: not significant (ns) > 0.05 and * ≤ 0.05.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques: Western Blot, Knock-Out, Control, Viability Assay, Immunofluorescence

A Dot plot of fork velocity in H1975 cells. Cells were treated with tuvusertib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. B Dot plot of fork velocity in H1975 cells. Cells were treated with niraparib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. C Representative immunofluorescent images of DNA fiber assay in H1975 cells. Cells were treated with 10 nM tuvusertib and 2.5 µM niraparib for 24 h prior to IdU (red) and CldU (green) labeling, then a DNA fiber assay was performed. Scale bars indicate 10 µm. D Dot plot of fork velocity in the experiment shown in Fig. 3C. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. E Dot plot of fork velocity in H1975 cells. Cells were transfected with siRNA for 24 h, were treated with 10 nM tuvusertib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. F Dot plot of H3K9me2 mean intensity per nuclei in H1975 cells. Cells were treated with niraparib and 2 µM UNC0642 for 24 h, then were carried on immunofluorescence analysis. The graph indicates the median of 200 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, * ≤ 0.05, ** ≤ 0.01, and **** ≤ 0.0001. G Dot plot of fork velocity in H1975 cells. Cells were treated with 10 nM tuvusertib, 2.5 µM niraparib, and 2 µM UNC0642 for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. H Dot plot of γH2A.X mean intensity per nuclei in S phase cells. Cells were treated with 100 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 each for 48 h, then an immunofluorescence analysis was performed. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, *** ≤ 0.001, and **** ≤ 0.0001. I Cell viability relative to untreated or UNC0642-treated cells in H1975 cells. Cells were treated with 100 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 for 6 days, then were carried on cell viability assay. The graph indicates the mean ± SD of three independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: not significant (ns) > 0.05, ** ≤ 0.01, and **** ≤ 0.0001.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: A Dot plot of fork velocity in H1975 cells. Cells were treated with tuvusertib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. B Dot plot of fork velocity in H1975 cells. Cells were treated with niraparib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. C Representative immunofluorescent images of DNA fiber assay in H1975 cells. Cells were treated with 10 nM tuvusertib and 2.5 µM niraparib for 24 h prior to IdU (red) and CldU (green) labeling, then a DNA fiber assay was performed. Scale bars indicate 10 µm. D Dot plot of fork velocity in the experiment shown in Fig. 3C. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. E Dot plot of fork velocity in H1975 cells. Cells were transfected with siRNA for 24 h, were treated with 10 nM tuvusertib for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. F Dot plot of H3K9me2 mean intensity per nuclei in H1975 cells. Cells were treated with niraparib and 2 µM UNC0642 for 24 h, then were carried on immunofluorescence analysis. The graph indicates the median of 200 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, * ≤ 0.05, ** ≤ 0.01, and **** ≤ 0.0001. G Dot plot of fork velocity in H1975 cells. Cells were treated with 10 nM tuvusertib, 2.5 µM niraparib, and 2 µM UNC0642 for 24 h prior to IdU and CldU labeling, then were carried on DNA fiber assay. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. H Dot plot of γH2A.X mean intensity per nuclei in S phase cells. Cells were treated with 100 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 each for 48 h, then an immunofluorescence analysis was performed. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, *** ≤ 0.001, and **** ≤ 0.0001. I Cell viability relative to untreated or UNC0642-treated cells in H1975 cells. Cells were treated with 100 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 for 6 days, then were carried on cell viability assay. The graph indicates the mean ± SD of three independent experiments and statistical significance by one-way ANOVA test with Tukey’s multiple comparisons test. P -value: not significant (ns) > 0.05, ** ≤ 0.01, and **** ≤ 0.0001.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques: Labeling, Transfection, Immunofluorescence, Viability Assay

A Dot plot of fork velocity in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 10 nM tuvusertib and 625 nM niraparib for 24 h prior to IdU and CldU labeling, then a DNA fiber assay was performed. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. B Dot plot of H3K9me2 mean intensity per nuclei in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 2.5 µM niraparib for 24 h, then were carried on immunofluorescence analysis. The graph indicates the median of 200 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. C Dot plot of fork velocity in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 10 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 for 24 h prior to IdU and CldU labeling, then a DNA fiber assay was performed. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, * ≤ 0.05, and **** ≤ 0.0001. D Western blot analysis of SMARCA4 WT and SMARCA4 KO cells. Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib for 48 h, then carried on western blot analysis. α-Tubulin was detected as loading control. E Dot plot of γH2A.X mean intensity per nuclei in S phase cells. Cells were transfected with siRNA for 24 h, then were treated with 62.5 nM tuvusertib and 625 nM niraparib for 48 h and 25 µM Mirin for 24 h prior to immunofluorescence analysis. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: ** ≤ 0.01 and **** ≤ 0.0001.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: A Dot plot of fork velocity in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 10 nM tuvusertib and 625 nM niraparib for 24 h prior to IdU and CldU labeling, then a DNA fiber assay was performed. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05 and **** ≤ 0.0001. B Dot plot of H3K9me2 mean intensity per nuclei in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 2.5 µM niraparib for 24 h, then were carried on immunofluorescence analysis. The graph indicates the median of 200 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. C Dot plot of fork velocity in SMARCA4 WT and SMARCA4 KO H1975 cells. Cells were treated with 10 nM tuvusertib, 625 nM niraparib, and 2 µM UNC0642 for 24 h prior to IdU and CldU labeling, then a DNA fiber assay was performed. The graph indicates the mean of 200 fibers and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: not significant (ns) > 0.05, * ≤ 0.05, and **** ≤ 0.0001. D Western blot analysis of SMARCA4 WT and SMARCA4 KO cells. Cells were treated with 62.5 nM tuvusertib and 625 nM niraparib for 48 h, then carried on western blot analysis. α-Tubulin was detected as loading control. E Dot plot of γH2A.X mean intensity per nuclei in S phase cells. Cells were transfected with siRNA for 24 h, then were treated with 62.5 nM tuvusertib and 625 nM niraparib for 48 h and 25 µM Mirin for 24 h prior to immunofluorescence analysis. PCNA-positive cells were defined as S phase cells. The graph indicates the median of 500 cells and statistical significance by Kruskal–Wallis test with Dunn’s multiple comparisons test. P -value: ** ≤ 0.01 and **** ≤ 0.0001.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques: Labeling, Immunofluorescence, Western Blot, Control, Transfection

A, B Body weight (B.W.) changes relative to day 0 and tumor growth in each group. H1975:SMARCA4 WT and SMARCA4 KO xenograft mice were treated with niraparib (50 mg/kg, Daily), tuvusertib (20 mg/kg, 4 days on/3 days off), or combination. The graph indicates the mean ± SD of n = 10 mice/group and statistical significance by two-way ANOVA test with Tukey’s multiple comparisons test. P -value: * ≤ 0.05.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: A, B Body weight (B.W.) changes relative to day 0 and tumor growth in each group. H1975:SMARCA4 WT and SMARCA4 KO xenograft mice were treated with niraparib (50 mg/kg, Daily), tuvusertib (20 mg/kg, 4 days on/3 days off), or combination. The graph indicates the mean ± SD of n = 10 mice/group and statistical significance by two-way ANOVA test with Tukey’s multiple comparisons test. P -value: * ≤ 0.05.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques:

PARP inhibition elevates H3K9me2-associated heterochromatin that increases ATR dependence for fork progression and cell survival, resulting in moderate synergistic cytotoxicity with ATR inhibition in SMARCA4 wild-type (WT) cells. In SMARCA4-deficient (Def) cells, Mus81 and Mre11 nucleases cooperate to exacerbate ATRi/PARPi-induced replication catastrophe. Therefore, ATRi and PARPi combination causes potent cytotoxicity in SMARCA4-deficient cells.

Journal: Cell Death Discovery

Article Title: PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells

doi: 10.1038/s41420-025-02306-1

Figure Lengend Snippet: PARP inhibition elevates H3K9me2-associated heterochromatin that increases ATR dependence for fork progression and cell survival, resulting in moderate synergistic cytotoxicity with ATR inhibition in SMARCA4 wild-type (WT) cells. In SMARCA4-deficient (Def) cells, Mus81 and Mre11 nucleases cooperate to exacerbate ATRi/PARPi-induced replication catastrophe. Therefore, ATRi and PARPi combination causes potent cytotoxicity in SMARCA4-deficient cells.

Article Snippet: ATRi (tuvusertib), ATMi (lartesertib), DNA-PKi (peposertib), and PARPi (niraparib) were provided by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Techniques: Inhibition

(A) Proliferation of Pmel-1 CD8 + T cells activated with gp100 ex vivo. CTV histograms of live, CD44 hi CD8 + T cells at indicated times post-activation are shown. Red histograms are un-activated CD8 + T cells that have largely died. The number of divisions is shown. (B) Immunoblots of CD8 + T whole-cell extracts prepared the same number of cells at 0 and 30 h post-activation. (C) CD8 + T cells were activated and treated with 5 μM AZD6738 (ATRi) from 0 to 24 h (blue) or 24 to 48 h (red). At 48 h, live CD8 + T cells (eFluor 780 − CD8 + TCRβ + ) were quantitated. (D) Unactivated CD8 + T cells were maintained in IL-7 and treated with ATRi from 0 to 24 or 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (E) CD8 + T cells were activated and treated with ATRi, 500 nM AZD0156 (ATMi), 5 μM olaparib (PARPi), or 500 nM AZD1775 (WEE1i) from 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (A and B) Two biological replicates. (C and D) Three biological replicates. (E) Two biological replicates; three technical replicates. (C–E) Mean and SD bars are shown. *p < 0.05, **p < 0.01, ****p < 0.0001, by ANOVA with Tukey’s multiple comparisons.

Journal: Cell reports

Article Title: Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression

doi: 10.1016/j.celrep.2022.111371

Figure Lengend Snippet: (A) Proliferation of Pmel-1 CD8 + T cells activated with gp100 ex vivo. CTV histograms of live, CD44 hi CD8 + T cells at indicated times post-activation are shown. Red histograms are un-activated CD8 + T cells that have largely died. The number of divisions is shown. (B) Immunoblots of CD8 + T whole-cell extracts prepared the same number of cells at 0 and 30 h post-activation. (C) CD8 + T cells were activated and treated with 5 μM AZD6738 (ATRi) from 0 to 24 h (blue) or 24 to 48 h (red). At 48 h, live CD8 + T cells (eFluor 780 − CD8 + TCRβ + ) were quantitated. (D) Unactivated CD8 + T cells were maintained in IL-7 and treated with ATRi from 0 to 24 or 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (E) CD8 + T cells were activated and treated with ATRi, 500 nM AZD0156 (ATMi), 5 μM olaparib (PARPi), or 500 nM AZD1775 (WEE1i) from 24 to 48 h. At 48 h, live CD8 + T cells were quantitated. (A and B) Two biological replicates. (C and D) Three biological replicates. (E) Two biological replicates; three technical replicates. (C–E) Mean and SD bars are shown. *p < 0.05, **p < 0.01, ****p < 0.0001, by ANOVA with Tukey’s multiple comparisons.

Article Snippet: Olaparib (PARPi) , AstraZeneca , N/A.

Techniques: Ex Vivo, Activation Assay, Western Blot

(A) EdU versus DNA plots of CD8 + T cells and fibroblasts. The percentage of cells in each cell cycle phase and the doubling time were used to estimate the length of G1, S, and G2/M. (B) The circumference of the circle represents the doubling time, and the lengths of G1, S, and G2/M are drawn to scale. (C) Immunoblot of MCM4 in the chromatin fraction prepared from CD8 + T cells treated with 5 μM AZD6738 (ATRi), 500 nM AZD0156 (ATMi), 5 μM olaparib (PARPi), or 500 nM AZD1775 (WEE1i) for 1 h. (D) Repli-seq analyses of the replication timing program of CD8 + T cells treated with ATRi (red) or DMSO (blue) for 1 h. Upper: whole genome. Lower: chromosome 1. Data were deposited at GEO: GSE183412. (E) EdU incorporation in early (2N–3N) and late (3N–4N) S phase in CD8 + T cells treated with ATRi for 1 h. 10 μM EdU was added from 30 to 60 min. (F) DNA combing analyses of CD8 + T cells and fibroblasts treated with ATRi for 1 h. Cells were treated with IdU from 30 to 40 min and CldU from 40 to 60 min of the treatment. (G) Immunoblots of MCM4 in the chromatin fraction prepared from CD8 + T cells treated with increasing concentrations of Ro-3306 (CDK1i), CVT-313 (CDK2i), or PHA-767491 (CDC7i) for 75 min. Cells were treated with ATRi from 15 to 75 min. (H) Immunoblot of RIF1 phosphoserine-2153 in whole-cell extracts prepared from CD8 + T cells treated with Ro-3306 for 75 min. Cells were treated with five ATRi’s from 15 to 75 min. (I) Immunoblot of MCM4 in chromatin fraction and CDC25A in the soluble fraction prepared from CD8 + T cells treated with ATRi and/or 5 mM HU in the sequence indicated. (J) Cartoon of a model in which ATR limits origin firing across active replicons. Green circles indicate origins that fired, and red circles indicate origins that have not fired. (A) CD8 + T cells: 12 biological replicates, 1–5 technical replicates; fibroblasts: 7 biological replicates, 1–2 technical replicates. (E) 10 biological replicates. (F) Left panel, CD8 + T cells DMSO: n = 179 fibers from 4 biological replicates, CD8 + T cells ATRi: n = 203 fibers from 3 biological replicates, fibroblasts DMSO: n = 30 fibers from 2 biological replicates, fibroblasts ATRi: n = 28 fibers from 2 biological replicates. Right panel, CD8 + T cells DMSO: n = 675 fibers from 5 biological replicates, CD8 + T cells ATRi: n = 520 fibers from 4 biological replicates, fibroblasts DMSO: n = 226 fibers from 2 biological replicates, fibroblasts ATRi: n = 219 fibers from 2 biological replicates. (C and G–I) Two biological replicates. (E and F) Mean and SD bars are shown. **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-tailed, unpaired t test.

Journal: Cell reports

Article Title: Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression

doi: 10.1016/j.celrep.2022.111371

Figure Lengend Snippet: (A) EdU versus DNA plots of CD8 + T cells and fibroblasts. The percentage of cells in each cell cycle phase and the doubling time were used to estimate the length of G1, S, and G2/M. (B) The circumference of the circle represents the doubling time, and the lengths of G1, S, and G2/M are drawn to scale. (C) Immunoblot of MCM4 in the chromatin fraction prepared from CD8 + T cells treated with 5 μM AZD6738 (ATRi), 500 nM AZD0156 (ATMi), 5 μM olaparib (PARPi), or 500 nM AZD1775 (WEE1i) for 1 h. (D) Repli-seq analyses of the replication timing program of CD8 + T cells treated with ATRi (red) or DMSO (blue) for 1 h. Upper: whole genome. Lower: chromosome 1. Data were deposited at GEO: GSE183412. (E) EdU incorporation in early (2N–3N) and late (3N–4N) S phase in CD8 + T cells treated with ATRi for 1 h. 10 μM EdU was added from 30 to 60 min. (F) DNA combing analyses of CD8 + T cells and fibroblasts treated with ATRi for 1 h. Cells were treated with IdU from 30 to 40 min and CldU from 40 to 60 min of the treatment. (G) Immunoblots of MCM4 in the chromatin fraction prepared from CD8 + T cells treated with increasing concentrations of Ro-3306 (CDK1i), CVT-313 (CDK2i), or PHA-767491 (CDC7i) for 75 min. Cells were treated with ATRi from 15 to 75 min. (H) Immunoblot of RIF1 phosphoserine-2153 in whole-cell extracts prepared from CD8 + T cells treated with Ro-3306 for 75 min. Cells were treated with five ATRi’s from 15 to 75 min. (I) Immunoblot of MCM4 in chromatin fraction and CDC25A in the soluble fraction prepared from CD8 + T cells treated with ATRi and/or 5 mM HU in the sequence indicated. (J) Cartoon of a model in which ATR limits origin firing across active replicons. Green circles indicate origins that fired, and red circles indicate origins that have not fired. (A) CD8 + T cells: 12 biological replicates, 1–5 technical replicates; fibroblasts: 7 biological replicates, 1–2 technical replicates. (E) 10 biological replicates. (F) Left panel, CD8 + T cells DMSO: n = 179 fibers from 4 biological replicates, CD8 + T cells ATRi: n = 203 fibers from 3 biological replicates, fibroblasts DMSO: n = 30 fibers from 2 biological replicates, fibroblasts ATRi: n = 28 fibers from 2 biological replicates. Right panel, CD8 + T cells DMSO: n = 675 fibers from 5 biological replicates, CD8 + T cells ATRi: n = 520 fibers from 4 biological replicates, fibroblasts DMSO: n = 226 fibers from 2 biological replicates, fibroblasts ATRi: n = 219 fibers from 2 biological replicates. (C and G–I) Two biological replicates. (E and F) Mean and SD bars are shown. **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-tailed, unpaired t test.

Article Snippet: Olaparib (PARPi) , AstraZeneca , N/A.

Techniques: Western Blot, Sequencing, Two Tailed Test

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression

doi: 10.1016/j.celrep.2022.111371

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Olaparib (PARPi) , AstraZeneca , N/A.

Techniques: Recombinant, Protease Inhibitor, Saline, Staining, Membrane, Cell Isolation, Flow Cytometry, Purification, Fluorescence, Software

(A) mCRPC patients were enrolled in a Phase Ib rucaparib/nivolumab co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: (A) mCRPC patients were enrolled in a Phase Ib rucaparib/nivolumab co-clinical trial at University of Chicago, and treated until disease progression or unacceptable toxicity. As part of the study, blood was processed to collect sera for ELISA based determination of PSA levels at baseline and every month on study. Data obtained was used to calculate percent change in PSA levels at approximately 90 days, relative to baseline values. Each bar represents a single patient. * indicates patient who progressed early at 41 days, as per RECIST guidelines; n = 7 patients. (B-C) B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with the indicated drug(s) and euthanized when untreated tumors reached approx. 2500 mm 3 . Tumor volume curves for duration of treatment are shown. (D-G) Single-cell suspensions were generated from harvested tumors and analyzed by flow cytometry for the indicated immune cell populations and their activation states. Data are represented relative to CD45+ immune cells. n=3 animals per treatment group from 2 independent experiments. Significance/p-values were calculated by one-way ANOVA/paired t-test and indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns = not statistically significant.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Generated, Flow Cytometry, Activation Assay

Subcutaneous Myc-CAP (STING lo ) and B6-Myc (STING hi ) tumors at 400-500mm 3 volumes were treated with either buparlisib (pan-PI3K inhibitor, 30mg/kg) or rucaparib (PARP inhibitor, 150mg/kg) by oral gavage daily for 7 days. At end of treatment, both (A) B6-Myc (STING hi ) and (B) Myc-CAP (STING lo ) tumors were harvested and protein extracts utilized for assessment of target inhibition with the indicated antibodies by Western blotting. n=2 mice per treatment group.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: Subcutaneous Myc-CAP (STING lo ) and B6-Myc (STING hi ) tumors at 400-500mm 3 volumes were treated with either buparlisib (pan-PI3K inhibitor, 30mg/kg) or rucaparib (PARP inhibitor, 150mg/kg) by oral gavage daily for 7 days. At end of treatment, both (A) B6-Myc (STING hi ) and (B) Myc-CAP (STING lo ) tumors were harvested and protein extracts utilized for assessment of target inhibition with the indicated antibodies by Western blotting. n=2 mice per treatment group.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Inhibition, Western Blot

B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with PARPi/PI3Ki +/- clodronate (to deplete macrophages) until untreated tumors reached 2500 mm 3 . Tumors were processed and stained for MHC-I by flow cytometry; n=3 animals per group; Significance/ p-values were calculated by one-way ANOVA, indicated as follows, **p < 0.01.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: B6-Myc (STING hi ) tumor-bearing syngeneic mice were treated with PARPi/PI3Ki +/- clodronate (to deplete macrophages) until untreated tumors reached 2500 mm 3 . Tumors were processed and stained for MHC-I by flow cytometry; n=3 animals per group; Significance/ p-values were calculated by one-way ANOVA, indicated as follows, **p < 0.01.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Staining, Flow Cytometry

(A) Syngeneic mice were engrafted with Myc-CAP (STING lo ) cells, and tumors were harvested when the tumor volume reached 400 mm 3 . Single cell suspensions of the tumors were treated with the indicated drug(s), in the presence or absence of GW4869 (MV biogenesis inhibitor). (B) Bone marrow derived macrophage (BMDMs) were co-cultured for 30 hours with supernatants (-/+ exogenous 50 units of DNase I pre-treatment for 30 minutes) from Myc-CAP cells that were treated with the indicated drug(s) for 36 hours. (C) cGAMP (10 μg/ml) was pre-incubated with 10 units of DNAse I or mock control for 30 minutes and then treated with BMDMs for 30 hours. (D-G) STING +/+ /STING -/- BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP and B6-Myc cancer cells, that were treated with the indicated drug(s) for 36 hours. Supernatants were collected from A-G at the end of treatment and analyzed for IFNβ1 by ELISA. (H) Myc-CAP (STING lo ) tumor-bearing mice were treated with the indicated drug(s) until tumors first reached approx. 2500 mm 3 . For the degerelix/rucaparib/buparlisib combination, additional cohorts of mice underwent concomitant treatment with STING antagonist H-151 or GW4869. Tumor volume was recorded daily for duration of experiment. For in vitro experiments, n=2 independent experiments and for in vivo experiments n= 3-4 animals /group. Significance/p-values were calculated by one-way ANOVA and are indicated as follows, *p < 0.05; **p < 0.01, ***p < 0.001; **** p< 0.0001; ns = not statistically significant;

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: (A) Syngeneic mice were engrafted with Myc-CAP (STING lo ) cells, and tumors were harvested when the tumor volume reached 400 mm 3 . Single cell suspensions of the tumors were treated with the indicated drug(s), in the presence or absence of GW4869 (MV biogenesis inhibitor). (B) Bone marrow derived macrophage (BMDMs) were co-cultured for 30 hours with supernatants (-/+ exogenous 50 units of DNase I pre-treatment for 30 minutes) from Myc-CAP cells that were treated with the indicated drug(s) for 36 hours. (C) cGAMP (10 μg/ml) was pre-incubated with 10 units of DNAse I or mock control for 30 minutes and then treated with BMDMs for 30 hours. (D-G) STING +/+ /STING -/- BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP and B6-Myc cancer cells, that were treated with the indicated drug(s) for 36 hours. Supernatants were collected from A-G at the end of treatment and analyzed for IFNβ1 by ELISA. (H) Myc-CAP (STING lo ) tumor-bearing mice were treated with the indicated drug(s) until tumors first reached approx. 2500 mm 3 . For the degerelix/rucaparib/buparlisib combination, additional cohorts of mice underwent concomitant treatment with STING antagonist H-151 or GW4869. Tumor volume was recorded daily for duration of experiment. For in vitro experiments, n=2 independent experiments and for in vivo experiments n= 3-4 animals /group. Significance/p-values were calculated by one-way ANOVA and are indicated as follows, *p < 0.05; **p < 0.01, ***p < 0.001; **** p< 0.0001; ns = not statistically significant;

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Derivative Assay, Cell Culture, Incubation, Control, Enzyme-linked Immunosorbent Assay, In Vitro, In Vivo

BMDMs were co-cultured with MVs isolated from Myc-CAP (STING lo ) cancer cells following 36 hr treatment with rucaparib (R-MVs), in the presence or absence of buparlisib at the indicated concentrations for 24 hrs. Protein extracts were harvested for assessment of PI3K target inhibition by Western Blotting; U= Untreated.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: BMDMs were co-cultured with MVs isolated from Myc-CAP (STING lo ) cancer cells following 36 hr treatment with rucaparib (R-MVs), in the presence or absence of buparlisib at the indicated concentrations for 24 hrs. Protein extracts were harvested for assessment of PI3K target inhibition by Western Blotting; U= Untreated.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Cell Culture, Isolation, Inhibition, Western Blot

(A) Experimental schema: Myc-CAP (STING lo ) cells were treated with rucaparib (0.5 µM) for 36 hours, followed by isolation of MVs from supernatant (R-MVs), which were then co-cultured with BMDMs in the presence/absence of buparlisib (1 µM) for 36 hours. BMDMs were directly treated with DMXAA (50 µg/ml). (B-C) Cellular metabolites and proteins extracted from co-cultured BMDMs (as per schema in A ) were used for cGAMP ELISA (B) and for assessment of activation of STING pathway by western blotting using indicated antibodies (C ), respectively. (D-E) Supernatants collected from experiment in (A) were used for IFN-α (D) and IFN-β ELISA (E) . ( F) Model for cGAS/STING pathway activation within suppressive macrophages (M2) following treatment with buparlisib and MVs (isolated from rucaparib-treated Myc-CAP cells); n=2 independent experiments. Significance/ p-values were calculated by one-way ANOVA and are indicated as follows, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: (A) Experimental schema: Myc-CAP (STING lo ) cells were treated with rucaparib (0.5 µM) for 36 hours, followed by isolation of MVs from supernatant (R-MVs), which were then co-cultured with BMDMs in the presence/absence of buparlisib (1 µM) for 36 hours. BMDMs were directly treated with DMXAA (50 µg/ml). (B-C) Cellular metabolites and proteins extracted from co-cultured BMDMs (as per schema in A ) were used for cGAMP ELISA (B) and for assessment of activation of STING pathway by western blotting using indicated antibodies (C ), respectively. (D-E) Supernatants collected from experiment in (A) were used for IFN-α (D) and IFN-β ELISA (E) . ( F) Model for cGAS/STING pathway activation within suppressive macrophages (M2) following treatment with buparlisib and MVs (isolated from rucaparib-treated Myc-CAP cells); n=2 independent experiments. Significance/ p-values were calculated by one-way ANOVA and are indicated as follows, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Isolation, Cell Culture, Enzyme-linked Immunosorbent Assay, Activation Assay, Western Blot

Myc-CAP (STING lo ) cells were treated with rucaparib (0.5 µM) for 36 hours, followed by isolation of MVs from supernatant (R-MVs), which were then co-incubated with BMDMs in the presence/absence of buparlisib (1 µM) for 36 hours. As a positive control, BMDMs were directly treated with DMXAA (50 µg/ml). At the end of treatment, BMDMs were analyzed by flow cytometry for macrophage activation markers to quantify frequency of CD45+CD11b+F4/80+ cells expressing MHC-II (A) and CD86 (B) . (C-E) Supernatants were collected for determination of M1-specific cytokines/chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were calculated by one-way ANOVA and are indicated as follow, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant. (F) Working Model: The combination of PARPi + PI3Ki induces intracellular DNA DSBs, that become associated with the surface of extracellular MVs following release into the TME. In addition, PI3Ki can inhibit AKT-mediated Ser-291 phosphorylation of cGAS, thus de-repressing its enzymatic activity. MV surface-associated DNA DSBs can secondarily activate the cGAS/STING pathway within TAMs only in the presence of concomitant PI3Ki, resulting in macrophage activation and M2 to M1 polarization, increased T cell infiltration, and tumor regression in c-myc driven PC.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: Myc-CAP (STING lo ) cells were treated with rucaparib (0.5 µM) for 36 hours, followed by isolation of MVs from supernatant (R-MVs), which were then co-incubated with BMDMs in the presence/absence of buparlisib (1 µM) for 36 hours. As a positive control, BMDMs were directly treated with DMXAA (50 µg/ml). At the end of treatment, BMDMs were analyzed by flow cytometry for macrophage activation markers to quantify frequency of CD45+CD11b+F4/80+ cells expressing MHC-II (A) and CD86 (B) . (C-E) Supernatants were collected for determination of M1-specific cytokines/chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were calculated by one-way ANOVA and are indicated as follow, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant. (F) Working Model: The combination of PARPi + PI3Ki induces intracellular DNA DSBs, that become associated with the surface of extracellular MVs following release into the TME. In addition, PI3Ki can inhibit AKT-mediated Ser-291 phosphorylation of cGAS, thus de-repressing its enzymatic activity. MV surface-associated DNA DSBs can secondarily activate the cGAS/STING pathway within TAMs only in the presence of concomitant PI3Ki, resulting in macrophage activation and M2 to M1 polarization, increased T cell infiltration, and tumor regression in c-myc driven PC.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Isolation, Incubation, Positive Control, Flow Cytometry, Activation Assay, Expressing, Phospho-proteomics, Activity Assay

BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP (STING lo ) cancer cells that were treated with the indicated drug(s) (rucaparib 0.5uM, buparlisib 1uM) for 36 hours. DMXAA (50ug/ml) was directly added to BMDMs. Following treatment, BMDMs were stained for expression of macrophage activation markers (A) MHC-II; (B) iNOS and suppressive marker (C) Arginase I on CD45+ CD11b+F4/80+ macrophages. (D-E) Supernatants were collected for determination of secreted chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were determined by one-way ANOVA (A) / Un-paired t-test (B), *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP (STING lo ) cancer cells that were treated with the indicated drug(s) (rucaparib 0.5uM, buparlisib 1uM) for 36 hours. DMXAA (50ug/ml) was directly added to BMDMs. Following treatment, BMDMs were stained for expression of macrophage activation markers (A) MHC-II; (B) iNOS and suppressive marker (C) Arginase I on CD45+ CD11b+F4/80+ macrophages. (D-E) Supernatants were collected for determination of secreted chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were determined by one-way ANOVA (A) / Un-paired t-test (B), *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Cell Culture, Staining, Expressing, Activation Assay, Marker

BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP (STING lo ) cancer cells that were treated with the indicated drug(s) (rucaparib 0.5uM, buparlisib 1uM) for 36 hours. DMXAA (50ug/ml) was directly added to BMDMs. Following treatment, BMDMs were stained for expression of macrophage activation markers (A) MHC-II; (B) iNOS and suppressive marker (C) Arginase I on CD45+ CD11b+F4/80+ macrophages. (D-E) Supernatants were collected for determination of secreted chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were determined by one-way ANOVA, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Journal: bioRxiv

Article Title: PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

doi: 10.1101/2020.07.17.198598

Figure Lengend Snippet: BMDMs were co-cultured for 36 hours with supernatants from Myc-CAP (STING lo ) cancer cells that were treated with the indicated drug(s) (rucaparib 0.5uM, buparlisib 1uM) for 36 hours. DMXAA (50ug/ml) was directly added to BMDMs. Following treatment, BMDMs were stained for expression of macrophage activation markers (A) MHC-II; (B) iNOS and suppressive marker (C) Arginase I on CD45+ CD11b+F4/80+ macrophages. (D-E) Supernatants were collected for determination of secreted chemokines by cytokine array; n=2 independent experiments; Significance/ p-values were determined by one-way ANOVA, *p < 0.05; **p < 0.01, ***p < 0.001, **** p< 0.0001, ns = not statistically significant.

Article Snippet: To test this hypothesis, mCRPC patients that had progressed on at least one-line of AR-targeted therapy in the castrate-resistant setting, were treated with PARPi rucaparib (Clovis Oncology) in combination with nivolumab (Bristol Myers Squibb) until disease progression and/or unacceptable toxicity.

Techniques: Cell Culture, Staining, Expressing, Activation Assay, Marker